C-reactive protein,anti-C-reactive protein antibodies and clinical atherosclerosis

Abstract

There has been considerable interest in the relationship between C-reactive protein (CRP) and atherosclerosis. We have previously demonstrated that individuals, especially those with rheumatoid arthritis and systemic lupus erythematosus, may produce antibodies to CRP. This study was therefore undertaken to determine the possible association between anti-CRP antibodies and atherosclerosis. A total of 103 individuals were identified with or without atherosclerosis, and without clinical rheumatic diseases. They were evaluated with respect to cholesterol, HDL, LDL, high-sensitivity (hs)CRP, and anti-CRP antibody levels, as well as use of statin medications. Individuals with atherosclerosis were much more likely to be taking a statin, and thus have lower lipid levels. However, there was no association between hsCRP or anti-CRP antibody levels with atherosclerosis, statin use, or each other. These observations suggest that anti-CRP antibody is not involved in atherosclerosis, and may represent an epiphenomenon.

Keywords

atherosclerosis autoantibodies C-reactive protein

References

1 Reeves WH Richards HB Satoh M . Autoantibodies. In: RG Lahita N Chiorazzi WH Reeves . (eds). Textbook of the autoimmune diseases. Lippincott, 2000: 81–100.

2 Rosenau BJ Schur PH . Antibody to serum Amyloid A. J Autoimmun 2004; 23: 179–182.

3 Bell SA Faust H Schmid A Meurer M . Auto antibodies to C-reactive protein (CRP) and other acute-phase proteins in systemic autoimmune disease. Clin Exp Immunol 1998; 113: 327–332.

4 Sjowall C Eriksson P Almer S Skogh T . Auto antibodies to C-reactive protein is a common finding in SLE, but not in primary Sjogren’s syndrome, rheumatoid arthritis or inflammatory bowel disease. J Autoimmun 2002; 19: 155–160.

5 Rosenau BJ Schur PH . Antibodies to C reactive protein. Ann Rheum Dis 2006; 65: 674–676.

6 Libby P Ridker PM . Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004; 116(suppl 6A): 9S–16S.

7 Albert MA Danielson E Rifai N . Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64–70.

8 Whicker JT Ritchie RF Johnson AM . New international reference preparation for proteins in human serum (RPPHS). Clin Chem 1994: 40; 934–938.

9 Hansson GK . Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685–1695.

10.

10 Fischer LM Schlienger RG Matter C . Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 2004; 93: 198–200.

11.

11 Wilson AM Ryan MC Boyle AJ . The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol 2006; 106: 291–297.

12.

12 Eaton RB Schnneider G Schur PH . Enzyme immunoassay for antibodies to nDNA: specificity and quality of antibodies. Arthritis Rheum 1983; 26: 52–62.

13.

13 Hoch S Schur PH Schwaber J . Frequency of anti-DNA antibody producing cells from normals and patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1983; 27: 28–37.

14.

14 Tan EM Feltkamp TE Smolen JS . Range of antinuclear antibodies in ‘healthy’ individuals. Arthritis Rheum 1997; 40:1601–1611.